Department of Otolaryngology-Head & Neck Surgery, Lewis Katz School of Medicine at Temple Hospital, Philadelphia, PA, USA.
Department of Otolaryngology-Head & Neck Surgery, Lewis Katz School of Medicine at Temple Hospital, Philadelphia, PA, USA.
Surg Oncol Clin N Am. 2024 Oct;33(4):723-733. doi: 10.1016/j.soc.2024.04.006. Epub 2024 Jun 5.
Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and Merkel cell carcinoma (MCC) comprise the majority of nonmelanoma skin cancers. Advances have been made in treatment. Sentinel node biopsy should be considered for locally advanced, clinically node-negative cSCCs and MCCs. BCC patients failing traditional surgery and/or radiation are candidates for systemic hedgehog inhibitor therapy. Immune checkpoint inhibitor treatment is available for patients who failed traditional treatment with surgery and/or radiation or who are not candidates for these modalities. Specifically, cemiplimab is approved for advanced BCC; cemiplimab and pembrolizumab for advanced cSCC; and avelumab, pembrolizumab, and retifanlimab-dlwr for recurrent/metastatic MCC.
基底细胞癌（BCC）、皮肤鳞状细胞癌（cSCC）和 Merkel 细胞癌（MCC）构成了大多数非黑色素瘤皮肤癌。在治疗方面取得了进展。对于局部晚期、临床无淋巴结转移的 cSCC 和 MCC，应考虑进行前哨淋巴结活检。对于传统手术和/或放疗失败的 BCC 患者，可考虑接受系统性 Hedgehog 抑制剂治疗。对于那些传统手术和/或放疗失败的患者，或不适合这些治疗方法的患者，免疫检查点抑制剂治疗是可用的。具体来说，cemizumab 获批用于晚期 BCC；cemizumab 和 pembrolizumab 用于晚期 cSCC；avelumab、pembrolizumab 和 retifanlimab-dlwr 用于复发性/转移性 MCC。
